

BIOCRYST PHARMACEUTICALS INC  
Form 8-K  
September 23, 2009

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549  
FORM 8-K  
CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934  
Date of Report (Date of earliest event reported): September 18, 2009  
BioCryst Pharmaceuticals, Inc.  
(Exact Name of Registrant as Specified in Charter)**

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**000-23186**  
(Commission  
File Number)

**62-1413174**  
(IRS Employer  
Identification No.)

**2190 Parkway Lake Drive, Birmingham, Alabama**  
(Address of Principal Executive Offices)

**35244**  
(Zip Code)

**(205) 444-4600**

(Registrant's telephone number, including area code)  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 210.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 1.01 Entry into a Material Definitive Agreement**

On September 18, 2009, BioCryst Pharmaceuticals, Inc. (the Company ) entered into a contract modification with the U.S. Department of Health & Human Services (HHS) to advance the development of intravenous (i.v.) peramivir. The modification increases the award under the original contract by \$77.2 million for a total of \$179.9 million and extends the term of the contract by 12 months for a total term of five years.

**Item 7.01 Regulation FD Disclosure**

On September 21, 2009, the Company issued a news release with respect to the modification. The news release is furnished as Exhibit 99.1 hereto and is incorporated by reference.

The information furnished is not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, is not subject to the liabilities of that section and is not deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press release dated September 21, 2009 entitled BioCryst Awarded Additional \$77.2 million by the U.S. Department of Health & Human Services to Develop Peramivir for Influenza.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 23, 2009

**BioCryst Pharmaceuticals, Inc.**

By:                   /s/ Alane Barnes  
                          Alane Barnes  
                          General Counsel, Corporate Secretary

---

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press release dated September 21, 2009 entitled BioCryst Awarded Additional \$77.2 million by the U.S. Department of Health & Human Services to Develop Peramivir for Influenza.